Paratek Pharmaceuticals is a biopharmaceutical company that develops and commercializes life-saving therapies for life-threatening diseases. Its lead products include NUZYRA, a broad-spectrum antibiotic for bacterial pneumonia and skin infections, and SEYSARA, a tetracycline for acne vulgaris. The company has license and collaboration agreements with Zai Lab and Allergan, a license agreement with Tufts University, and a contract with Biomedical Advanced Research and Development Authority. It was founded in 1996 and is headquartered in Boston, Massachusetts.